Idenix Suits Target Gilead Hep C Drug Nearing Approval

Law360, New York (December 2, 2013, 4:24 PM EST) -- Idenix Pharmaceuticals Inc. told two federal courts Sunday that Gilead Sciences Inc. is on course to infringe its intellectual property if the U.S. Food and Drug Administration approves Gilead's new drug application for a Hepatitis C treatment as expected this month.

The FDA voted 15-0 in October to support approval of Gilead's sofosbuvir for treatment of hepatitis C virus, and final approval is expected around Dec. 8, Idenix said. Idenix claims in suits filed Sunday in Massachusetts and Delaware federal court that its provisional patent application...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.